Avalo Therapeutics, Inc.

NasdaqCM:AVTX Stock Report

Market Cap: US$3.7m

Avalo Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Avalo Therapeutics has a total shareholder equity of $14.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $29.3M and $14.6M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$10.18m
EquityUS$14.70m
Total liabilitiesUS$14.58m
Total assetsUS$29.27m

Recent financial health updates

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Aug 10
Is Cerecor (NASDAQ:CERC) A Risky Investment?

Recent updates

Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007

Aug 01

Avalo Therapeutics announces one-for-twelve reverse stock split

Jul 06

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Aug 10
Is Cerecor (NASDAQ:CERC) A Risky Investment?

Cerecor enters into $35M debt financing agreement with Horizon Technology Finance

Jun 07

What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Mar 10
What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Jan 18
Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Armistice Capital adds 2.5M Cerecor shares for $6.5M

Jan 13

Cerecor slumps 12% on stock and pre-funded warrants offering

Jan 07

Cerecor gains on CERC-002 data in mid-stage COVID-19 study

Jan 05

Cerecor trades higher as FDA accepts IND application for CERC-007

Dec 22

Dosing underway in Cerecor's early-stage CERC-007 study in multiple myeloma

Dec 16

Cerecor on go with CERC-007 early-stage study in multiple myeloma

Dec 08

How Much Of Cerecor Inc. (NASDAQ:CERC) Do Institutions Own?

Nov 27
How Much Of Cerecor Inc. (NASDAQ:CERC) Do Institutions Own?

Cerecor teams up with Frontiers CDG Consortium on CERC-801 pivotal study in rare metabolic genetic disorder

Nov 17

Financial Position Analysis

Short Term Liabilities: AVTX's short term assets ($12.7M) exceed its short term liabilities ($6.0M).

Long Term Liabilities: AVTX's short term assets ($12.7M) exceed its long term liabilities ($8.6M).


Debt to Equity History and Analysis

Debt Level: AVTX is debt free.

Reducing Debt: AVTX has no debt compared to 5 years ago when its debt to equity ratio was 79%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVTX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AVTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.1% each year


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.